Sustained-release effervescent floating matrix tablets of baclofen: development, optimization and in vitro-in vivo evaluation in healthy human volunteers by Gande, S & Rao, YM
Sustained-release effervescent floating matrix tablets of baclofen: 
development, optimization and in vitro-in vivo evaluation in healthy 
human volunteers
Gande S , Rao YM.
Centre for Biopharmaceutics and Pharmacokinetics, University College of Pharmaceutical 
Sciences, Kakatiya University. Warangal-506009 Andhra Pradesh, India.
Received 15 Feb 2011; Revised 20 June 2011; Accepted 20 June 2011
ABSTRACT
Background and the purpose of the study: Baclofen, a centrally acting skeletal muscle relaxant, 
is indicated in the long-term treatment of spasticity. It is difficult to formulate baclofen sustained 
release dosage forms because its absorption on arrival to colon (or even before) is low or 
nonexistent. In the present investigation efforts were made to improve the bioavailability of 
baclofen by increasing the residence time of the drug through sustained-release matrix tablet 
formulation via gastroretentive mechanism.
Methods: Tablets were prepared by wet granulation technique. The influence of gas generating 
and gel forming agents, amount of baclofen and total weight of tablet on physical properties, 
in vitro buoyancy, floating lag time, drug release, DSC, X-ray studies were investigated. The 
release mechanisms were explored and explained by applying zero order, first order, Higuchi 
and Korsmeyer equations. The selected formulations were subjected to stability study for the 
period of three months. 
Results: For all formulations, kinetics of drug release from tablet followed Higuchi’s square 
root of time kinetic treatment heralding diffusion as predominant mechanism of drug release. 
Formulations containing 20 mg and 40 mg (F-1 and F-7) showed similar release profiles. There 
was no significant change in the selected formulations, when subjected to accelerated stability 
conditions over a period of three months. X-ray imaging in six healthy human volunteers 
revealed a mean gastric retention period of 5.50±0.7 hrs for the selected formulation. 
Conclusion:Stable, sustained release effervescent floating matrix tablets of baclofen could be 
prepared by wet granulation technique.
Keywords: Floating tablets, Gastroretentive, Hydrophilic polymers, Mean dissolution time, 
Sustained release.
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INTRODUCTION
Baclofen, a centrally acting skeletal muscle relaxant, 
is indicated in the long-term treatment of spasticity 
resulting  from  multiple  sclerosis  and  spinal  cord 
injuries.  Baclofen  is  rapidly  and  extensively 
absorbed and eliminated. The half-life of the drug is 
~2.5 to 4 hrs in plasma (1). Baclofen has absorption 
window in upper G.I. tract, and as result display low 
bioavailability (2). 
Baclofen  is  difficult  to  formulate  in  to  sustained 
release  dosage  forms  because  on  arrival  to  colon 
(or  even  before)  its  absorption  is  diminished  or 
nonexistent, In the present investigation efforts were 
made to increase the residence time of baclofen at or 
above the absorption window through preparation of 
gastroretentive tablet considering the fact that it is 
stable under gastric condition (3). 
The  principle  of  buoyancy  offers  a  simple  and 
practical  approach  to  achieve  increased  residence 
time  in  the  stomach.  The  impact  of  formulation 
variables on the release rate, mean dissolution time 
and release mechanism was also evaluated by the 
use of mathematical models. 
MATERIAL AND METHODS
Materials
Lioresal  (25  mg  tablets,  batch  number  82001 
P,  Novartis  Pharma,  India)  was  purchased  from 
market, Baclofen was a generous gift from Natco P
harmaceuticals,(Hyderabad, India), Hydroxy propyl 
methyl cellulose (HPMC K15M, 100M, 6cps) were 
obtained from Colorcon Asia Private Limited (India), 
PVPK 30 was obtained from BASF (Germany). All 
excipients  were  of  USP/NF  grades  and  all  other 
chemicals used were of analytical grades.
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The  HPLC  system  consisted  of  2695  separation 
module (Waters, USA), equipped with 2996 PDA 
detector. The data were collected and analyzed via 
empower software. A 5 µm C18 ACE column (250 
mm  X  4.6  mm  I.D)  (Advanced  chromatography 
technologies) was used. The flow rate of the mobile 
phase was 0.6 ml/minute.
Methods
Kinetic modeling of drug release 
The  dissolution  profiles  of  all  the  batches  were 
fitted to zero order, first order, Higuchi and Peppas 
equations (4) (equation 1-4 respectively).
Mt = M0 + k0t                                                         (1)
lnMt = lnM0 + k1t                                                   (2)
Mt = M0 – kHt1/2                                                                                           (3)
Mt/Mα =Kt
n                                                            (4)
In these equations, Mt is the cumulative amount of 
drug released at any specified time (t), M0 is the dose 
of the drug incorporated in the delivery system and 
Mt/Mα is a fraction of drug released at time (t).  k0, k1, 
kH and K are rate constants for zero order, first order, 
Higuchi and korsmeyer model respectively, n is the 
release exponent. The n value is used to characterize 
different release mechanisms as given in table 1 for 
cylindrical shaped matrices (5).
The dissolution data were also fitted to the well-
known exponential Zero Order equation, which is 
often used to describe drug release behavior from 
polymeric systems.
The best fit with higher correlation (r2 > 98) was found 
with Higuchi’s equation for all the formulations. 
The mean dissolution time was calculated by the 
following expression:
Mean dissolution time (MDT)  =
∫0
∞ (M max- M (t) dt)
M max
M(t) and M max are the amount of drug released at 
time t, and the maximal amount of drug released (6), 
respectively.
Solubility studies
The equilibrium solubility of baclofen was measured 
in 0.1M hydrochloric acid (pH of 1.2), acetate buffer 
(pH of 4.5), and phosphate buffer of pH 6.8. Excess 
amounts of the drug were added to 50 ml-stoppered 
conical  flasks  (n=3).  The  flasks  were  shaken 
mechanically at 37°C±0.5 °C for 24 hrs. After 2 
days of equilibrium, aliquots were withdrawn and 
filtered  (0.22μm  pore  syringe  filter).  Then,  the 
filtered samples were diluted with an appropriate 
amount of 0.1 M hydrochloric acid to obtain final 
solutions of pH 1.2 which were subjected to HPLC 
analysis.
Drug-excipient interactions
The  physicochemical  compatibilities  of  the  drug 
and the used excipients were tested by differential 
scanning  calorimetric  (DSC)  analysis.  DSC 
thermograms  of  the  drug  alone,  drug-excipient 
physical mixture and tablets were derived from a 
DSC  (2-C,  Perkin-Elmer,  New York,  NY)  with  a 
thermal analysis data station system, computer, and 
plotter interface. The instrument was calibrated with 
an  indium  standard.  The  samples  (2-4  mg)  were 
heated  (20-300  °C)  at  a  constant  scanning  speed       
(10 °C/min) in sealed aluminum pans, using nitrogen 
as purging gas.
Preparation  of  baclofen  sustained  release  matrix 
tablets
All the tablet formulations were prepared by using 
wet granulation technique. The composition of the 
20, 25, 30 and 40 mg baclofen tablets are given 
in  table  2.  Polyvinyl  pyrrolidone  was  accurately 
weighed  and  dissolved  in  isopropyl  alcohol. 
All  excipients  except  magnesium  stearate  were 
accurately  weighed  and  passed  through  No.  40 
mesh  ASTM.  Calculated  amount  of  the  drug, 
polymer (HPMC K 15M or 100M or 6 cps etc) and 
filler  Microcrystalline  cellulose  (Avicel  pH101) 
were mixed thoroughly. A sufficient volume of the 
specified granulating agents were added slowly to 
achieve  the  granulation  endpoint. After  the  time 
that enough cohesiveness was obtained, granules 
were dried at room temperature to evaporate the 
IPA and then were dried at 50 °C for 30 minutes. 
The semi-dried granules were passed through No. 
10  mesh  ASTM  and  drying  was  continued  for 
another 1 hour and 30 minutes. The granules were 
collected and passed through # 22 mesh ASTM. 
Magnesium stearate was passed through # 80 mesh 
ASTM  to  lubricate  the  granules.  The  granules 
were  compressed  using  8  mm  round  standard 
concave punches. The composition of the different 
formulations is shown in table 2.
Evaluation of tablets
Thickness
The thickness of the tablets was determined by using 
vernier calipers (Mitutoyo, Japan). Ten tablets from 
Diffusion exponent (n) Overall solute diffusion mechanism
0.45 Fickian diffusion
0.45<n<0.89 Anomalous (non-Fickian) diffusion
0.89 Case-II transport
n>0.89 Super case-II transport
Table 1. Diffusion exponent and solute release mechanism for 
cylindrical shape.
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each batch were used. Thickness values are reported 
in  millimeters.  Mean  and  SD  values  were  also 
calculated.
Average weight of the dosage unit
To  study  weight  variation,  10  tablets  of  each 
formulation  were  weighed  using  an  electronic 
balance  (Mettler Toledo,  Switzerland). Values  are 
reported in milligrams. Mean and SD value were 
also calculated.
Drug content
Twenty tablets were first weighed individually and 
then placed in a mortar and powdered with a pestle. 
An amount equivalent to 40 mg of the drug was taken 
into a 50 ml volumetric flask, treated with 10 ml of 
diluting solution (30 % Methanol : 4% Glacial acetic 
acid:  66%  Water)  and  sonicated  for  15  min.  The 
solution was filtered through a 0.22 μm PVDF syringe 
filter SLGV Millipore, and then the drug content was 
measured by HPLC as per USP-NF 29 (7).
Hardness test
For each formulation, the hardness of 6 tablets was 
determined  using  a  hardness  tester  (Sotax  HT1, 
Sotax, Switzerland). Hardness values are reported 
in Newton’s (N). Mean and SD values were also 
calculated.
Friability test
For each formulation, 6.5 g of dedusted tablets were 
weighed, placed in a friabilator (Electrolab, Mumbai, 
India) and subjected to 100 revolutions for 4 min. 
The tablets were then dedusted and re-weighed. The 
friability  was  calculated  as  the  percentage  of  the 
weight loss.
In vitro release studies
In vitro release studies of the control, and baclofen 
matrix  tablets  were  monitored.  The  release 
experiments were performed in a 1000-ml dissolution 
medium containing hydrochloric acid (pH of 1.2), 
kept at 37 °C ± 0.5 °C and stirred at 50 rpm, using 
USP dissolution apparatus II. A 5-ml sample was 
withdrawn  through  a  0.45  μm  filter  and  replaced 
with  another  5  ml  of  a  suitable  fresh  dissolution 
medium at pre-selected intervals up to 12 hrs. The 
amount of the drug was determined by HPLC as per 
USP-NF 29 (7).
Stability studies
Formulations F-1 and F-7 were subjected to 25°C± 
2°C/60% ± 5 %RH and 40°C ± 2°C /75 ± 5%RH 
(Newtronic, Mumbai, India) in closed HDPE bottles 
along with 1 g desiccant for 3 months.
Abdominal X-ray imaging
For the X-ray experiment 40 mg of the drug of the 
formulation F-7 was replaced with barium sulfate 
and its other ingredients were kept constant. This 
amount was determined experimentally to allow X-
ray visibility but not to hinder tablet buoyancy. 
After overnight fasting, the volunteers were fed with 
a low calorie food. After ½ hour, a barium sulfate-
labeled tablet was given to every subject with 200 
ml  of  water.  The  volunteers  were  asked  to  take 
200 ml water after every 1 hour. At different time 
intervals (0, 0.5, 1.5, 4 and 6 hrs post-administration 
of tablets), volunteers were exposed to abdominal 
X-ray  imaging  (Genesis  50,  Josef  Betschart AG, 
Brunnen, Switzerland) in standing position.
A radiograph was made just before administration 
of the tablet, at zero time, to ensure the absence of 
radio-opaque material in the stomach. The distance 
between the source of X-rays and the subject was 
kept constant for all images. Thus, the observation 
of  the  floating  tablet  movements  could  be  easily 
observed (8) and the mean gastric retention period 
could be estimated.
RESULTS AND DISCUSSION 
Baclofen solubility in physiological solutions of pH 
of 1.2, 4.5 and 6.8 and at 37 °C were 25, 5.8 and 
5.1mg/ml, respectively.
The  DSC  analysis  of  the  drug  alone  elicited  an 
endothermic  peak  at  210°C  (theoretical  value  is 
208°C) (9) and it was found that the endothermic 
peaks of physical mixtures as well as tablet reflected 
the characteristic features of baclofen alone. From the 
results of thermograms of baclofen and its physical 
mixtures (1:1) which is shown in figure 1, it appears 
that there was no drug excipient interaction.
Preparation  and  In  vitro  evaluation  of  baclofen 
gastro retentive floating tablets
Granules were prepared and compressed with the 
ratio  22  and  25%  of  the  floating  agent  when  the 
total weight of the tablets were 180 mg and 200 mg 
respectively  to  get  the  floating  lag  time  within  5 
min with the same concentration of same polymer. 
The formulations with 200 mg tablet weight were 
compressed  with  22.2%  floating  agent  and  the 
floating lag time was found to be higher than 10 
minutes. The results of physical evaluation are listed 
in table 3. 
Figure  2,  shows  chromatograms  of  the  standard 
baclofen  (10µg/ml)  and  sample.  Figure  3  and  4, 
show percent of the drug release of the prepared 
baclofen tablets and marketed tablets at pH 1.2. 
In vitro buoyancy and Mean dissolution time
Floating  lag  time  of  all  formulations  and  floated 
for more than 10 hrs in dissolution medium pH 1.2 
(Table 4) was less than 4 min. MDT values for all 
formulations are listed in table 4. A higher value of 
MDT indicates a higher drug retarding ability of the 
polymer and vice versa. Lowest MDT was observed 
with F-6 formulation which contained HPMC K15M 
polymer.Gande et al / DARU 2011 19 (3) 202-209 205
Figure 1. DSC thermograms of pure drug (A) physical mixture (B) and tablet (C).
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Formula
Compression 
Force (Tonnage)
Hardness (N) Friability (%) Thickness (mm) Weight (mg) Drug Content (%)
F-1 3 95±5 0.12 3.12±0.05 180±2.2 101.41±0.64
F-2 3 88±6 0.14 3.13±0.08 180±1.9 101.65±0.82
F-3 3 70±8 0.15 3.64±0.06 225±3.1 100.22±0.55
F-4 3 75±5 0.21 3.56±0.04 190±2.2 99.82±1.41
F-5 3 90±7 0.24 3.62±0.12 200±1.9 99.68±0.92
F-6 3 90±5 0.11 3.15±0.24 180±2.4 98.97±1.47
F-7 3 85±5 0.13 3.45± 0.36 200±1.8 100.22± 0.82
F-8 3 87±5 0.11 3.48±0.28 200±2.1 99.96±0.91
Table 3. Physical evaluation of baclofen floating tablets.
Formula F-1 F-2 F-3 F-4 F-5 F-6 F-7 F-8
Baclofen (mg) 20 20 25 25 30 30 40 40
Avicel 101 (mg) 24.2 24.2 30.25 24.1 24 24 24 24
Methocel K 100M (mg) 65 - - 65 65 - 60 -
Methocel K 15M (mg) - 65 81.25 - - 60 - 60
HPMC E6-LV (mg) 20 20 25 20 20 17.2 17 17
Sodium bicarbonate (mg) 40 40 50 45 50 40 50 50
PVPK 30 (mg) 9 9 11.25 9 9 7 7 7
Mg Stearate 1.8 1.8 2.25 1.9 2.0 1.8 2.0 2.0
Total (mg) 180 180 225 190 200 180 200 200
Remarks Floated Floated Not floated Floated Floated Floated Floated Floated
Table 2. Formulation compositions of baclofen floating tablets.
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figure 2. Chromatograms of baclofen samples. a: Standard 10 µg/ml, b: Sample solutions.
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Figure 3. Dissolution profile of lioresal with GRDDS floating tablets F-1, F-2 and F-4.Gande et al / DARU 2011 19 (3) 202-209 207
Formula Floating Lag time (Sec) MDT (10th Hour) % Release (12 Hour)
F-1 180±20 3.63 93.0
F-2 190±20 3.80 84.1
F-3 ND ND ND
F-4 170±30 3.58 95.1
F-5 210±15 3.20 101.1
F-6 200±15 2.90 100.0
F-7 240±15 3.60 105.8
F-8 240±15 3.15 101.5
*ND – Not determined
Formula
Zero Order 
(r2)
K0
First Order 
(r2)
K Values
Higuchi
(r2)
Kh
Peppas
(r2)
N Value
F-1 0.930 6.80 0.353 0.115 0.992 28.8 0.981 0.611
F-2 0.955 6.48 0.387 0.118 0.986 26.9 0.949 0.649
F-3 - - - - - - - -
F-4 0.923 6.41 0.329 0.108 0.993 27.25 0.966 0.566
F-5 0.891 7.50 0.461 0.235 0.994 29.82 0.969 0.569
F-6 0.886 7.22 0.469 0.235 0.985 28.67 0.980 0.580
F-7 0.926 9.58 0.487 0.303 0.997 33.79 0.955 0.555
F-8 0.887 9.12 0.458 0.294 0.996 32.84 0.927 0.527
Table 4. Floating lag time, MDT and % of the release of the prepared baclofen tablets.
Table 5. Release parameters of baclofen floating tablets.
Effect  of  the  polymer  grade  on  the  release  of 
baclofen
Formulations  containing  HPMC  E6-LV  in 
combination with Methocel K100M or K15M were 
compared  to  explore  the  effect  of  polymers  and 
amount of the drug release (Table 2). Percent of the 
release of drug at the end of twelth hour for F-1, 
F-2, F-4, F-5 and F-6 were 93.0%, 84.1%, 95.1%, 
101.1% and 100.0% respectively (Table 4). These 
values indicated a decrease of the drug release by 
increase in polymer. Increasing the weight of tablet 
(F-3)  stopped  its  floating  and  hence  the  in  vitro 
release profile was not studied. R2 values obtained 
from  zero  order  equation  for  F-1,  F-2,  F-4,  F-5 
and F-6 were 0.930, 0.955, 0.923, 0.912 and 0.886 
respectively  (Table  5).  The  best  linearity  values 
found in Higuchi’s equation plot were 0.99, 0.986, 
0.993, 0.994 and 0.985 respectively indicating the 
release  of  drug  from  matrix  as  a  square  root  of 
time dependent process based on diffusion. The n 
values for korsmeyer and peppas equation (F-1, F-
2, F-4, F-5 and F-6) were found to be 0.61, 0.65, 
0.56,  0.56  and  0.58  respectively,  indicating  non-
Fickian (anomalous) release, coupled diffusion, and 
polymer matrix relaxation, 0.5<n<0.89. Thus, it was 
proposed  that  these  formulations  delivered  their 
active compounds by coupled diffusion and erosion 
(10). 
In formulations F-7 and F-8, the percent of the drug 
release at tenth hour was 105.8% and 101.5%. R2 
values  obtained  from  zero  order  equations  were 
0.926  and  0.887  respectively  (Table  5).  The  n 
values were found to be 0.55 and 0.52 respectively, 
indicating non fickian (anomalous) release, coupled 
diffusion. The best linearity was found in Higuchi’s 
equation plot (F-7) which was 0.997 indicating the 
release of drug from matrix as a square root of time 
dependent process based on diffusion mechanism. 
The (F-8) formulation value was near to the zero 
order release. 
The  formulations  containing  HPMC  K100M 
polymer showed zero order release and was found 
to  follow  predominantly  non  fickian  (anomalous) 
release coupled diffusion mechanism.
Immediate release tablets showed 100% drug release 
within  15  min  (11),  the  drug  release  rates  from 
the  prepared  SR  matrix  tablets  were  significantly 
retarded when compared with the rates from standard 
lioresal 25mg tablets.
No  significant  change  was  observed  in  baclofen 
release rate (Figure 5) and tablets were buoyant for 
12 hrs in 0.1N HCl when subjected to stability study 
for three months. 
The mean gastric retention period
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Figure 5. Influence of storage condition on % drug release for 3 months.
tablet was 270±10s. X-ray images taken at different 
intervals after administration of the barium sulfate-
loaded  tablets  in  six  healthy  human  volunteers 
showed  that  tablet  was  more  or  less  at  the  same 
position in stomach for the first 3 hrs and moved 
slightly downwards and remained within the stomach 
till the end of 6 hrs. The mean gastric retention period 
was 5.50±0.77 hrs.
From the results of this study may concluded that, 
drug load, amount of soluble component, type of 
the polymer and the polymer content of the matrix 
affected significantly the release profile of baclofen. 
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